InvestorsHub Logo

Lemoncat

10/22/19 10:10 PM

#275051 RE: DesireToLearn #275048

I would guess between $10M and $40M. We have no idea how many patients we need and making it global makes it harder to price.

williamssc

10/22/19 10:18 PM

#275053 RE: DesireToLearn #275048

Feedback from the September share holder meeting provided by Yooper61 - Mgt said that B was embraced by the FDA. The fact the FDA has approved moving forward with P3, with such a modest sample size is impressive. The FDA is fine with the primary endpoint being high dose every 3 weeks. The trial size requested is 300 active drug recipients. They would go 2:1 drug:placebo, so 450 trial size.